<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63906">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273960</url>
  </required_header>
  <id_info>
    <org_study_id>IM140-103</org_study_id>
    <secondary_id>2014-001429-33</secondary_id>
    <nct_id>NCT02273960</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy in Adult Subjects With ITP</brief_title>
  <acronym>ITP</acronym>
  <official_title>Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of BMS-986004 when
      administered in subjects with ITP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-Term Period: Safety measured by number of subjects with adverse events (AEs), serious adverse events (SAEs), ECG abnormalities</measure>
    <time_frame>Day 1 to Day 141</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-Term Period: Safety measured by number of subjects with laboratory abnormalities including safety biomarkers of d-Dimer and Thrombin anti-Thrombin (TAT)</measure>
    <time_frame>Day 1 to Day 141</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-Term Extension Period: Safety measured by number of subjects with AEs, SAEs, ECG abnormalities</measure>
    <time_frame>Day 1 to Day 398</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-Term Extension Period: Safety measured by number of subjects with laboratory abnormalities including safety biomarkers of d-Dimer and TAT</measure>
    <time_frame>Day 1 to Day 398</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short-Term Period: Response rate (RR) of BMS-986004</measure>
    <time_frame>Day 1 to Day 141</time_frame>
    <description>RR is defined as the proportion of subjects who are responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-Term Extension Period: Response rate (RR) of BMS-986004</measure>
    <time_frame>Day 1 to Day 398</time_frame>
    <description>RR is defined as the proportion of subjects who are responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of BMS-986004</measure>
    <time_frame>From Day 1 till Day 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986004</measure>
    <time_frame>From Day 1 till Day 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough) of BMS-986004</measure>
    <time_frame>From Day 1 till Day 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of BMS-986004</measure>
    <time_frame>From Day 1 till Day 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC accumulation index (AI_AUC); ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose of BMS-986004</measure>
    <time_frame>From Day 1 till Day 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax accumulation index (AI_Cmax); ratio of Cmax at steady-state to Cmax after the first dose of BMS-986004</measure>
    <time_frame>From Day 1 till Day 141</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Immune Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Arm A: BMS-986004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986004 solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: BMS-986004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986004 solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: BMS-986004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986004 solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: BMS-986004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986004 solution intravenously as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986004</intervention_name>
    <arm_group_label>Arm A: BMS-986004</arm_group_label>
    <arm_group_label>Arm B: BMS-986004</arm_group_label>
    <arm_group_label>Arm C: BMS-986004</arm_group_label>
    <arm_group_label>Arm D: BMS-986004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  â‰¥18 years old, diagnosed with persistent or chronic ITP

        Exclusion Criteria:

          -  Secondary immune thrombocytopenia

          -  Drug induced thrombocytopenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Univ. Of Southern Calif. /Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>John B.Amos Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mass General Hosp</name>
      <address>
        <city>Boston</city>
        <state>Maine</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center - Univ Of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rutgers- Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0025</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0026</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences/Mc Master Univ Med Ctre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Arnold, Site 0011</last_name>
      <phone>905-525-9140</phone>
      <phone_ext>X22945</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chisinau</city>
        <zip>MD 2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Oddzial Hematologiczny</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Grosicki, Site 0029</last_name>
      <phone>+48323499751</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Gabinet Lekarski Prof. Dr Hab. Krzysztof Giannopoulos</name>
      <address>
        <city>Lublin</city>
        <zip>20-601</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Giannopoulos, Site 0028</last_name>
      <phone>+48502038268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0030</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0032</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0031</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire</state>
        <zip>G4 OSF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>October 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
